MedTrace Logo

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab

NCT00875238 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 133

Last updated 2018-02-19

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for increased risk of cardiac effects.

PURPOSE: This clinical trial is studying side effects involving the heart in women with breast cancer receiving doxorubicin and trastuzumab.

Conditions

Interventions

BIOLOGICAL

trastuzumab

DRUG

doxorubicin hydrochloride

GENETIC

polymorphism analysis

OTHER

laboratory biomarker analysis

OTHER

questionnaire administration

PROCEDURE

assessment of therapy complications

PROCEDURE

magnetic resonance imaging

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Carrie G Lenneman, MD, MSCI · Vanderbilt-Ingram Cancer Center & Univ. of Louisville

  • Daniel Lenihan, MD · Vanderbilt University

  • Douglas B Sawyer, MD, PhD · Vanderbilt University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00875238 on ClinicalTrials.gov